You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
诺诚健华(09969.HK)抑制剂新药研究申请获国家药监局受理
阿思达克 04-20 10:57
诺诚健华(09969.HK)公布,旗下新型多靶点受体酪氨酸激(酉每)抑制剂ICP-033,新药研究申请已获国家药品监督管理局受理。

该产品为公司具有全球自主知识产权的1类创新药,计划单用或/和免疫疗法及其他靶向药联合治疗肝癌、肾细胞癌、大肠癌及其他实体肿瘤,可抑制肿瘤血管形成,改善肿瘤微环境,抑制肿瘤生长、侵袭和转移,从而发挥靶点特异性抗肿瘤作用。

诺诚健华联合创始人、董事长兼CEO崔霁松表示,ICP-033为公司第六个进入临床阶段的创新药,将进一步丰富实体瘤领域的产品管线。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account